Cargando…

BOLERO-2 - will this change practice in advanced breast cancer?

The benefit of endocrine therapy has always been limited by the eventual development of acquired resistance. For the first time, clinical research has identified a therapeutic agent, everolimus, that targets the mammalian target of rapamycin (mTOR), which in combination with the aromatase inhibitor...

Descripción completa

Detalles Bibliográficos
Autor principal: Johnston, Stephen RD
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446325/
https://www.ncbi.nlm.nih.gov/pubmed/22713135
http://dx.doi.org/10.1186/bcr3126